Direct oral anticoagulants in hypercoagulable states

Journal of Thrombosis and Thrombolysis

Volumn 43, Issue 1, 2017, Pages 79-85

  Kunk, Paul R ^a   Brown, Jacqueline ^a   McShane, Melissa ^a   Palkimas, Surabhi ^a   Gail Macik, B ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Antiphospholipid syndrome; Apixaban; Direct oral anticoagulant; Heparin induced thrombocytopenia; Rivoraxaban

Indexed keywords

APIXABAN; RIVAROXABAN; ANTICOAGULANT AGENT; HEPARIN; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL FEATURE; DRUG EFFICACY; DRUG SAFETY; EXPLORATORY RESEARCH; FOLLOW UP; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERCOAGULABILITY; RECURRENT DISEASE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; ADULT; AGED; CHEMICALLY INDUCED; FEMALE; MALE; MIDDLE AGED; THROMBOPHILIA; THROMBOSIS;

ADULT; AGED; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HEMORRHAGE; HEPARIN; HUMANS; MALE; MIDDLE AGED; PYRAZOLES; PYRIDONES; RECURRENCE; RETROSPECTIVE STUDIES; RIVAROXABAN; THROMBOPHILIA; THROMBOSIS;

EID: 84986274539     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-016-1420-x     Document Type: Article

References (34)

1. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363:2499–2510
2. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369:799–808
3. Greinacher A (2015) Heparin-Induced thrombocytopenia. N Engl J Med 373:1883–1884
4. Kelton JG, Arnold DM, Bates SM (2013) Nonheparin anticoagulants for heparin-induced thrombocytopenia. N Engl J Med 368:737–744
5. Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S, Crowther M (2012) Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e495S–e530S
6. Pengo V, Ruffatti A, Legnani C, Gresele P, Barcellona D, Erba N, Testa S, Marongiu F, Bison E, Denas G et al (2010) Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 8:237–242
7. Krauel K, Hackbarth C, Furll B, Greinacher A (2012) Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies. Blood 119:1248–1255
8. Walenga JM, Prechel M, Jeske WP, Hoppensteadt D, Maddineni J, Iqbal O, Messmore HL, Bakhos M (2008) Rivaroxaban–an oral, direct factor Xa inhibitor–has potential for the management of patients with heparin-induced thrombocytopenia. Br J Haematol 143:92–99
9. Walenga JM, Prechel M, Hoppensteadt D, Escalante V, Chaudhry T, Jeske WP, Bakhos M (2013) Apixaban as an alternate oral anticoagulant for the management of patients with heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 19:482–487
10. Erkan D, Aguiar CL, Andrade D, Cohen H, Cuadrado MJ, Danowski A, Levy RA, Ortel TL, Rahman A, Salmon JE et al (2014) 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 13:685–696
11. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, PG, D.E.G., Koike T, Meroni PL et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306
12. Castellucci LA, Le Gal G, Rodger MA, Carrier M (2014) Major bleeding during secondary prevention of venous thromboembolism in patients who have completed anticoagulation: a systematic review and meta-analysis. J Thromb Haemost 12:344–348
13. Schaefer JK, McBane RD, Black DF, Williams LN, Moder KG, Wysokinski WE (2014) Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients. Thromb Haemost 112:947–950
14. Son M, Wypasek E, Celinska-Lowenhoff M, Undas A (2015) The use of rivaroxaban in patients with antiphospholipid syndrome: a series of 12 cases. Thromb Res 135:1035–1036
15. Win K, Rodgers GM (2014) New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome. Am J Hematol 89:1017
16. Noel N, Dutasta F, Costedoat-Chalumeau N, Bienvenu B, Mariette X, Geffray L, Sene D, Chaidi RB, Michot JM, Fain O et al (2015) Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. Autoimmun Rev 14:680–685
17. Bachmeyer C, Elalamy I (2014) Rivaroxaban as an effective treatment for recurrent superficial thrombophlebitis related to primary antiphospholipid syndrome. Clin Exp Dermatol 39:840–841
18. Delgado MG, Rodriguez S, Garcia R, Sanchez P, Saiz A, Calleja S (2015) Antiphospholipid syndrome of late onset: a difficult diagnosis of a recurrent embolic stroke. J Stroke Cerebrovasc Dis 24:e209–e211
19. Joalland F, de Boysson H, Darnige L, Johnson A, Jeanjean C, Cheze S, Augustin A, Auzary C, Geffray L (2014) Seronegative antiphospholipid syndrome, catastrophic syndrome, new anticoagulants: learning from a difficult case report. Rev Med Interne 35:752–756
20. Sciascia S, Breen K, Hunt BJ (2015). Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism. Blood Coagul Fibrinolysis 26:476–477
21. Signorelli F, Nogueira F, Domingues V, Mariz HA, Levy RA (2016). Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases. Clin Rheumatol 35:801–805
22. Betancur JF, Bonilla-Abadia F, Hormaza AA, Jaramillo FJ, Canas CA, Tobon GJ (2016) Direct oral anticoagulants in antiphospholipid syndrome: a real life case series. Lupus 25:658–662
23. Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, Laskin C, Fortin P, Anderson D, Kearon C et al (2003) A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 349:1133–1138
24. Finazzi G, Marchioli R, Brancaccio V, Schinco P, Wisloff F, Musial J, Baudo F, Berrettini M, Testa S, D’Angelo A et al (2005) A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 3:848–853
25. Agnelli G, Buller HR, Cohen A, Gallus AS, Lee TC, Pak R, Raskob GE, Weitz JI, Yamabe T (2015) Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost 13:2187–2191
26. Vigano D’Angelo S, Comp PC, Esmon CT, D’Angelo A (1986) Relationship between protein C antigen and anticoagulant activity during oral anticoagulation and in selected disease states. J Clin Invest 77:416–425
27. Woller SC, Stevens SM, Kaplan DA, Branch DW, Aston VT, Wilson EL, Gallo HM, Johnson EG, Rondina MT, Lloyd JF et al (2016) Apixaban for the secondary prevention of thrombosis among patients with antiphospholipid syndrome: study rationale and design (ASTRO-APS). Clin Appl Thromb Hemost 22:239–247
28. Linkins LA, Warkentin TE, Pai M, Shivakumar S, Manji R, Wells PS, Wu CM, Nazi I, Crowther MA (2015) Rivaroxaban for treatment of suspected or confirmed heparin-induced thrombocytopenia study. In: ASH annual conference, volume abstract 3468. Orlando, FL
29. Hantson P, Lambert C, Hermans C (2015) Rivaroxaban for arterial thrombosis related to heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 26:205–206
30. Sartori M, Favaretto E, Cini M, Legnani C, Cosmi B (2015) Rivaroxaban in the treatment of heparin-induced thrombocytopenia. J Thromb Thrombolysis 40:392–394
31. Mirdamadi A (2013) Dabigatran, a direct thrombin inhibitor, can be a life-saving treatment in heparin-induced thrombocytopenia. ARYA Atheroscler 9:112–114
32. Ng HJ, Than H, Teo EC (2015) First experiences with the use of rivaroxaban in the treatment of heparin-induced thrombocytopenia. Thromb Res 135:205–207
33. Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW et al (2015) Idarucizumab for dabigatran reversal. N Engl J Med 373:511–520
34. Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, Mathur VS, Castillo J, Bronson MD, Leeds JM et al (2015) Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 373:2413–2424